(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -51.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Stoke Therapeutics's revenue in 2025 is $205,632,000.On average, 13 Wall Street analysts forecast STOK's revenue for 2025 to be $11,071,017,185, with the lowest STOK revenue forecast at $10,412,456,445, and the highest STOK revenue forecast at $11,976,895,184. On average, 13 Wall Street analysts forecast STOK's revenue for 2026 to be $1,992,474,661, with the lowest STOK revenue forecast at $671,697,684, and the highest STOK revenue forecast at $4,198,110,525.
In 2027, STOK is forecast to generate $3,552,172,676 in revenue, with the lowest revenue forecast at $1,645,602,209 and the highest revenue forecast at $6,297,165,788.